{"id":"intrathecal-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Neurotoxicity (chemical arachnoiditis, transient paraplegia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Leukoencephalopathy (with repeated dosing)"}]},"_chembl":{"chemblId":"CHEMBL2074969","moleculeType":"Small molecule","molecularWeight":"841.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that blocks dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and DNA/RNA synthesis. When administered intrathecally (directly into the cerebrospinal fluid), it achieves high local concentrations in the CNS to treat or prevent leptomeningeal metastases and CNS leukemias. This route bypasses the blood-brain barrier and delivers cytotoxic concentrations directly to malignant cells in the meninges and brain.","oneSentence":"Intrathecal methotrexate is a chemotherapy agent delivered directly into the cerebrospinal fluid to inhibit dihydrofolate reductase and disrupt DNA synthesis in cancer cells, particularly those in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:40.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leptomeningeal metastases (prophylaxis and treatment)"},{"name":"CNS leukemia (acute lymphoblastic leukemia with CNS involvement)"},{"name":"Lymphomatous meningitis"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT04881838","phase":"PHASE3","title":"CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2021-03-01","conditions":"Pediatric Anaplastic Large Cell Lymphoma","enrollment":172},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05656248","phase":"PHASE2","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-01-17","conditions":"Myeloid Neoplasm","enrollment":25},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT07258043","phase":"","title":"Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2025-07-23","conditions":"Acute Lymphobkastic Leukemia, Leukemia, Overall Survival","enrollment":45},{"nctId":"NCT05146739","phase":"PHASE1","title":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-10","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome","enrollment":8},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT05519579","phase":"PHASE2","title":"Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2023-06-30","conditions":"Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT01760226","phase":"EARLY_PHASE1","title":"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":"Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma","enrollment":4},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07175415","phase":"PHASE1, PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","enrollment":42},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT05751044","phase":"PHASE1, PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT06516679","phase":"PHASE2","title":"Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-12-11","conditions":"Leukemia, Lymphoid","enrollment":40},{"nctId":"NCT02494882","phase":"PHASE1","title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-06-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT06099366","phase":"PHASE2","title":"Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children","status":"RECRUITING","sponsor":"Hee Young Ju","startDate":"2024-03-05","conditions":"Lymphoblastic Leukemia in Children","enrollment":116},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT06034561","phase":"PHASE2","title":"Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2024-04-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":50},{"nctId":"NCT05959720","phase":"","title":"Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-05","conditions":"Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality","enrollment":180},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT00619879","phase":"","title":"Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2007-03-26","conditions":"Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":81},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":"Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT06861348","phase":"PHASE2","title":"Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-01","conditions":"Leukemia, Lymphocytic, Acute","enrollment":23},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT00801216","phase":"PHASE2","title":"High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2007-01","conditions":"B-cell Lymphomas","enrollment":40},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT06554626","phase":"PHASE2","title":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-08-15","conditions":"Precursor B-Cell Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT06543992","phase":"PHASE2","title":"Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-13","conditions":"Leptomeningeal Metastasis of Breast Cancer","enrollment":22},{"nctId":"NCT05740449","phase":"PHASE1, PHASE2","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"WITHDRAWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":""},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT02385110","phase":"PHASE2","title":"Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Leukemia","enrollment":18},{"nctId":"NCT06190457","phase":"","title":"Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2015-09-30","conditions":"Lymphoma, Non-Hodgkin, Child, Only","enrollment":16},{"nctId":"NCT03962465","phase":"PHASE1","title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2022-07-22","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT04006561","phase":"","title":"Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-03-01","conditions":"Primary CNS Lymphoma, Brain Lymphoma","enrollment":36},{"nctId":"NCT03194932","phase":"PHASE1","title":"Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-07-11","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT03349281","phase":"PHASE1","title":"Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL","status":"COMPLETED","sponsor":"Julio Barredo, MD","startDate":"2019-03-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT03564470","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic","enrollment":120},{"nctId":"NCT02200978","phase":"PHASE4","title":"A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia","status":"COMPLETED","sponsor":"South China Children's Leukemia Group","startDate":"2011-09","conditions":"Childhood Acute Promyelocytic Leukemia","enrollment":176},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT02776605","phase":"PHASE2","title":"Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2016-06","conditions":"ALL","enrollment":30},{"nctId":"NCT01158885","phase":"PHASE2","title":"Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08","conditions":"Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":2},{"nctId":"NCT05054426","phase":"PHASE3","title":"Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-08","conditions":"Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma","enrollment":488},{"nctId":"NCT01861002","phase":"PHASE1","title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2013-05-22","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood","enrollment":15},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":3154},{"nctId":"NCT00671658","phase":"PHASE2","title":"Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT01104025","phase":"PHASE2","title":"Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":31},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT02836158","phase":"PHASE2, PHASE3","title":"Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2010-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":100},{"nctId":"NCT02657785","phase":"PHASE2, PHASE3","title":"Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2010-09","conditions":"Primary Central Nervous System Lymphoma","enrollment":100},{"nctId":"NCT03515200","phase":"PHASE1","title":"Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-04-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":12},{"nctId":"NCT04356222","phase":"PHASE4","title":"Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis","status":"UNKNOWN","sponsor":"Hui Bu","startDate":"2020-06","conditions":"Leptomeningeal Metastasis, Durvalumab","enrollment":30},{"nctId":"NCT04356118","phase":"PHASE4","title":"Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis","status":"UNKNOWN","sponsor":"Hui Bu","startDate":"2020-06","conditions":"Leptomeningeal Metastasis","enrollment":30},{"nctId":"NCT03071276","phase":"PHASE2","title":"Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":37},{"nctId":"NCT00853008","phase":"PHASE4","title":"Treatment of High Risk Adult Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2003-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT02212561","phase":"PHASE1","title":"Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-08","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)","enrollment":19},{"nctId":"NCT01540812","phase":"","title":"Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2012-02","conditions":"Acute Lymphoblastic Leukemia","enrollment":418},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT01953770","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2008-02","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":3000},{"nctId":"NCT01887587","phase":"PHASE1","title":"Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia","status":"TERMINATED","sponsor":"Ehab L Atallah","startDate":"2013-06","conditions":"Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":5},{"nctId":"NCT01661413","phase":"","title":"Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2012-05-07","conditions":"Acute Leukemia","enrollment":88},{"nctId":"NCT00392990","phase":"PHASE2","title":"Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-02-06","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT00866749","phase":"PHASE2","title":"Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-12","conditions":"Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":120},{"nctId":"NCT02535806","phase":"PHASE2","title":"Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults","status":"TERMINATED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2015-07","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":2},{"nctId":"NCT01448096","phase":"PHASE2","title":"Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2011-08","conditions":"Large B Cell Diffuse Lymphoma","enrollment":33},{"nctId":"NCT00004228","phase":"PHASE3","title":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":"Lymphoma","enrollment":393},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":"Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase","enrollment":1},{"nctId":"NCT02676323","phase":"PHASE1","title":"Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-05-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":19},{"nctId":"NCT00133991","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-07","conditions":"Leukemia, Lymphoma","enrollment":23}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"PULMONARY EMBOLISM"},{"count":1,"reaction":"ANAL ULCER"},{"count":1,"reaction":"ANORECTAL DISCOMFORT"},{"count":1,"reaction":"CLOSTRIDIUM TEST POSITIVE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DRUG TOXICITY"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"FUNGAL INFECTION"},{"count":1,"reaction":"GENERALISED TONIC-CLONIC SEIZURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rheumatrex","Methotrexate","Rheumatrex®"],"phase":"marketed","status":"active","brandName":"Intrathecal Methotrexate","genericName":"Intrathecal Methotrexate","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intrathecal methotrexate is a chemotherapy agent delivered directly into the cerebrospinal fluid to inhibit dihydrofolate reductase and disrupt DNA synthesis in cancer cells, particularly those in the central nervous system. Used for Leptomeningeal metastases (prophylaxis and treatment), CNS leukemia (acute lymphoblastic leukemia with CNS involvement), Lymphomatous meningitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}